Network-based stratification of tumor mutations

Nature Methods

Volumn 10, Issue 11, 2013, Pages 1108-1118

  Hofree, Matan ^a   Shen, John P ^b   Carter, Hannah ^b   Gross, Andrew ^b   Ideker, Trey ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA;

ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE EXPRESSION; GENE INTERACTION; GENE LOCATION; GENE SEQUENCE; HISTOLOGY; HUMAN; LUNG ADENOCARCINOMA; METHYLATION; MUTATION RATE; NETWORK BASED STRATIFICATION; OVARY ADENOCARCINOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; SOMATIC MUTATION; STRATIFICATION; SURVIVAL TIME; TUMOR GROWTH; UTERINE CERVIX CARCINOMA;

HUMANS; MUTATION; NEOPLASMS;

EID: 84887084951     PISSN: 15487091     EISSN: 15487105     Source Type: Journal    
DOI: 10.1038/nmeth.2651     Document Type: Article

References (68)

1. The International Cancer Genome Consortium. International network of cancer genome projects. Nature 464, 993-996 (2010).
2. The Cancer Genome Atlas Research Network. Integrated genomic analyses of ovarian carcinoma. Nature 474, 609-615 (2011).
3. The Cancer Genome Atlas Research Network. Integrated genomic characterization of endometrial carcinoma. Nature 497, 67-73 (2013).
4. Brunham, L.R. & Hayden, M.R. Whole-genome sequencing: the new standard of care? Science 336, 1112-1113 (2012).
5. Chin, L., Andersen, J.N. & Futreal, P.A. Cancer genomics: from discovery science to personalized medicine. Nat. Med. 17, 297-303 (2011).
6. Konstantinopoulos, P.A., Spentzos, D. & Cannistra, S.A. Gene-expression profling in epithelial ovarian cancer. Nat. Clin. Pract. Oncol. 5, 577-587 (2008).
7. Konstantinopoulos, P.A. et al. Gene expression profle of BRCAness that correlates with responsiveness to chemotherapy and with outcome in patients with epithelial ovarian cancer. J. Clin. Oncol. 28, 3555-3561 (2010).
8. Reis-Filho, J.S. & Pusztai, L. Gene expression profling in breast cancer: classifcation, prognostication, and prediction. Lancet 378, 1812-1823 (2011).
9. Esteva, F.J. et al. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy. Clin. Cancer Res. 11, 3315-3319 (2005).
10. The Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 487, 330-337 (2012).
11. Raspe, E., Decraene, C. & Berx, G. Gene expression profling to dissect the complexity of cancer biology: pitfalls and promise. Semin. Cancer Biol. 22, 250-260 (2012).
12. Mardis, E.R. Genome sequencing and cancer. Curr. Opin. Genet. Dev. 22, 245-250 (2012).
13. Carter, H. et al. Cancer-specifc high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res. 69, 6660-6667 (2009).
14. Greenman, C. et al. Patterns of somatic mutation in human cancer genomes. Nature 446, 153-158 (2007).
15. Wang, K. et al. Exome sequencing identifes frequent mutation of ARID1A in molecular subtypes of gastric cancer. Nat. Genet. 43, 1219-1223 (2011).
16. Dulak, A.M. et al. Exome and whole-genome sequencing of esophageal adenocarcinoma identifes recurrent driver events and mutational complexity. Nat. Genet. 45, 478-486 (2013).
17. Allegra, C.J. et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. J. Clin. Oncol. 27, 2091-2096 (2009).
18. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 490, 61-70 (2012).
19. Lawrence, M.S. et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 499, 214-218 (2013).
20. Kreeger, P.K. & Lauffenburger, D.A. Cancer systems biology: a network modeling perspective. Carcinogenesis 31, 2-8 (2010).
21. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
22. Waddington, C.H. Canalization of development and the inheritance of acquired characters. Nature 150, 563-565 (1942).
23. Vandin, F., Upfal, E. & Raphael, B.J. Algorithms for detecting signifcantly mutated pathways in cancer. J. Comput. Biol. 18, 507-522 (2011).
24. Vaske, C.J. et al. Inference of patient-specifc pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics 26, i237-i245 (2010).
25. Ciriello, G., Cerami, E., Sander, C. & Schultz, N. Mutual exclusivity analysis identifes oncogenic network modules. Genome Res. 22, 398-406 (2012).
26. Chuang, H.Y., Lee, E., Liu, Y.T., Lee, D. & Ideker, T. Network-based classifcation of breast cancer metastasis. Mol. Syst. Biol. 3, 140 (2007).
27. Dutkowski, J. & Ideker, T. Protein networks as logic functions in development and cancer. PLoS Comput. Biol. 7, e1002180 (2011).
28. Lee, I., Blom, U.M., Wang, P.I., Shim, J.E. & Marcotte, E.M. Prioritizing candidate disease genes by network-based boosting of genome-wide association data. Genome Res. 21, 1109-1121 (2011).
29. Szklarczyk, D. et al. The STRING database in 2011: functional interaction networks of proteins, globally integrated and scored. Nucleic Acids Res. 39, D561-D568 (2011).
30. Cerami, E.G. et al. Pathway Commons, a web resource for biological pathway data. Nucleic Acids Res. 39, D685-D690 (2011).
31. Vanunu, O., Magger, O., Ruppin, E., Shlomi, T. & Sharan, R. Associating genes and protein complexes with disease via network propagation. PLoS Comput. Biol. 6, e1000641 (2010).
32. Lee, D.D. & Seung, H.S. Learning the parts of objects by non-negative matrix factorization. Nature 401, 788-791 (1999).
33. Monti, S., Tamayo, P., Mesirov, J. & Golub, T. Consensus clustering: a resampling-based method for class discovery and visualization of gene expression microarray data. Mach. Learn. 52, 91-118 (2003).
34. Yang, D. et al. Association of BRCA1 and BRCA2 mutations with survival, chemotherapy sensitivity, and gene mutator phenotype in patients with ovarian cancer. J. Am. Med. Assoc. 306, 1557-1565 (2011).
35. Smoot, M.E., Ono, K., Ruscheinski, J., Wang, P.L. & Ideker, T. Cytoscape 2.8: new features for data integration and network visualization. Bioinformatics 27, 431-432 (2011).
36. Cole, C. et al. Inhibition of FGFR2 and FGFR1 increases cisplatin sensitivity in ovarian cancer. Cancer Biol. Ther. 10, 495-504 (2010).
37. Wysham, W.Z. et al. BRCAness profle of sporadic ovarian cancer predicts disease recurrence. PLoS ONE 7, e30042 (2012).
38. Tibshirani, R., Hastie, T., Narasimhan, B. & Chu, G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc. Natl. Acad. Sci. USA 99, 6567-6572 (2002).
39. Le Page, C. et al. Gene expression profling of primary cultures of ovarian epithelial cells identifes novel molecular classifers of ovarian cancer. Br. J. Cancer 94, 436-445 (2006).
40. Tothill, R.W. et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin. Cancer Res. 14, 5198-5208 (2008)
41. Gyorffy, B., Lánczky, A. & Szállási, Z. Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr. Relat. Cancer 19, 197-208 (2012).
42. Bonome, T. et al. A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. Cancer Res. 68, 5478-5486 (2008).
43. Reva, B., Antipin, Y. & Sander, C. Predicting the functional impact of protein mutations: application to cancer genomics. Nucleic Acids Res. 39, e118 (2011).
44. Carter, H., Douville, C., Stenson, P.D., Cooper, D.N. & Karchin, R. Identifying Mendelian disease genes with the variant effect scoring tool. BMC Genomics 14 (suppl. 3), s3 (2013).
45. Stamatoyannopoulos, J.A. et al. Human mutation rate associated with DNA replication timing. Nat. Genet. 41, 393-395 (2009).
46. Rabiner, L.R. & Gold, B. Theory and Application of Digital Signal Processing (Prentice Hall, 1975).
47. Turner, N. & Grose, R. Fibroblast growth factor signalling: from development to cancer. Nat. Rev. Cancer 10, 116-129 (2010).
48. Birrer, M.J. et al. Whole genome oligonucleotide-based array comparative genomic hybridization analysis identifed fbroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas. J. Clin. Oncol. 25, 2281-2287 (2007).
49. Futreal, P.A. et al. A census of human cancer genes. Nat. Rev. Cancer 4, 177-183 (2004).
50. Vogelstein, B. et al. Cancer genome landscapes. Science 339, 1546-1558 (2013).
51. Simon, D.N. & Wilson, K.L. The nucleoskeleton as a genome-associated dynamic 'network of networks'. Nat. Rev. Mol. Cell Biol. 12, 695-708 (2011).
52. Liu, Y. et al. Integrated analysis of gene expression and tumor nuclear image profles associated with chemotherapy response in serous ovarian carcinoma. PLoS ONE 7, e36383 (2012).
53. Strauss, B.S. Role in tumorigenesis of silent mutations in the TP53 gene. Mutat. Res. 457, 93-104 (2000).
54. Kimchi-Sarfaty, C. et al. A "silent" polymorphism in the MDR1 gene changes substrate specifcity. Science 315, 525-528 (2007).
55. Sauna, Z.E. & Kimchi-Sarfaty, C. Understanding the contribution of synonymous mutations to human disease. Nat. Rev. Genet. 12, 683-691 (2011).
56. Salzman, D.W. & Weidhaas, J.B. miRNAs in the spotlight: making 'silent' mutations speak up. Nat. Med. 17, 934-935 (2011).
57. Rand, W.M. Objective criteria for the evaluation of clustering methods. J. Am. Stat. Assoc. 66, 846-850 (1971).
58. Cai, D., He, X., Wu, X. & Han, J. Non-negative matrix factorization on manifold. in 8th IEEE Int. Conf. Data Mining 63-72 (IEEE, 2008).
59. Brunet, J.P., Tamayo, P., Golub, T.R. & Mesirov, J.P. Metagenes and molecular pattern discovery using matrix factorization. Proc. Natl. Acad. Sci. USA 101, 4164-4169 (2004).
60. Verhaak, R.G. et al. Integrated genomic analysis identifes clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
61. Ruan, J. & Zhang, W. Identifying network communities with a high resolution. Phys. Rev. E 77, 016104 (2008).
62. Verhaak, R.G. et al. Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J. Clin. Invest. 123, 517-525 (2013).
63. Schaefer, C.F. et al. PID: the Pathway Interaction Database. Nucleic Acids Res. 37, D674-D679 (2009).
64. Tusher, V.G., Tibshirani, R. & Chu, G. Signifcance analysis of microarrays applied to the ionizing radiation response. Proc. Natl. Acad. Sci. USA 98, 5116-5121 (2001).
65. Andersen, P.K. & Gill, R.D. Cox's regression model for counting processes: a large sample study. Ann. Stat. 10, 1100-1120 (1982).
66. Stenson, P.D. et al. The Human Gene Mutation Database (HGMD) and its exploitation in the felds of personalized genomics and molecular evolution. Curr. Protoc. Bioinformatics 39, 1.13 (2012).
67. Hansen, R.S. et al. Sequencing newly replicated DNA reveals widespread plasticity in human replication timing. Proc. Natl. Acad. Sci. USA 107, 139-144 (2010).
68. Kent, W.J. et al. The human genome browser at UCSC. Genome Res. 12, 996-1006 (2002).